SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001326190-24-000006
Filing Date
2024-03-27
Accepted
2024-03-27 07:04:30
Documents
15
Period of Report
2024-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20240327x8k.htm   iXBRL 8-K 44848
2 EX-99.1 alt-20240327xex99d1.htm EX-99.1 178043
3 GRAPHIC alt-20240327xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-24-000006.txt   368821

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20240327.xsd EX-101.SCH 3134
5 EX-101.LAB alt-20240327_lab.xml EX-101.LAB 15902
6 EX-101.PRE alt-20240327_pre.xml EX-101.PRE 10115
18 EXTRACTED XBRL INSTANCE DOCUMENT alt-20240327x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 24785747
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)